Insider Trading March 17, 2026

Ironwood Director Sells $20.5M in Stock Amid Recent Share Volatility

Alexander J. Denner disposed of Class A shares in two tranches as company posted Q4 2025 misses and reaffirmed 2026 guidance

By Priya Menon IRWD
Ironwood Director Sells $20.5M in Stock Amid Recent Share Volatility
IRWD

Alexander J. Denner, a director at Ironwood Pharmaceuticals, executed sales of Class A common stock totaling $20.5 million on March 17, 2026. The transactions were filed with the SEC and occurred while the stock experienced notable short-term weakness, even as the company reiterated its 2026 outlook and met liquidity requirements under its credit agreement.

Key Points

  • Director Alexander J. Denner sold Class A common shares on March 17, 2026, totaling $20.5 million via two tranches at $3.05 and $3.31 per share.
  • Ironwood reported Q4 2025 EPS of -$0.01 and revenue of $47.71 million, missing consensus estimates; full-year 2025 Linzess sales were $864.5 million and total revenue $296.2 million.
  • The company reaffirmed 2026 guidance, including adjusted EBITDA above $300 million, and confirmed it met liquidity conditions under its Credit Agreement with Wells Fargo as administrative agent.

Alexander J. Denner, a director of Ironwood Pharmaceuticals Inc (NASDAQ:IRWD), sold shares of the company's Class A Common Stock on March 17, 2026, for proceeds totaling $20.5 million, according to a Form 4 filed with the Securities and Exchange Commission.

The disposition was carried out in two separate blocks. Denner sold 6,725,000 shares at $3.05 per share and an additional 5,800 shares at $3.31 per share. The combined sales on that date produced the $20.5 million figure disclosed in the SEC filing.

The timing of Denner's sale coincides with heightened near-term movement in the stock. Ironwood's shares declined nearly 12% over the prior week, though the share price remained up 124% over the preceding 12 months as noted in the filing and company disclosures.

Separately, the filing records that on March 13, 2026, Denner acquired 4,451 shares of Class A Common Stock at no cost. Those shares were issued under the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.

After accounting for the March transactions, Denner retains indirect holdings of 9,188,635 shares through Sarissa Capital Management LP and related funds. The filing states that Denner disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.


Company financials and analyst moves

Ironwood reported its fourth-quarter 2025 results showing an EPS loss of $0.01, below the expected loss of $0.02, and revenue of $47.71 million, under the forecast of $62.43 million. The company disclosed fourth-quarter Linzess U.S. net sales of $163.2 million and total revenue for the quarter of $47.7 million. For the full year 2025, Linzess sales reached $864.5 million and total revenue was $296.2 million.

Following the results, Jefferies raised its price target on Ironwood to $3.70 from $0.70 and maintained a Hold rating, while increasing its Linzess peak sales estimate to $478 million. Citizens also adjusted its price target upward to $10.00 from $8.00 and maintained a Market Outperform rating, citing the company's reiterated 2026 guidance and confidence in Linzess cash-flow generation.

Ironwood reaffirmed its 2026 guidance, including adjusted EBITDA exceeding $300 million. In addition, an SEC filing indicated the company confirmed it met the liquidity conditions required under its existing Credit Agreement and notified Wells Fargo Bank, the administrative agent for that agreement, that it satisfied the outlined liquidity requirements.


Context and implications

The Form 4 disclosure documents the mechanics and scale of Denner's March 17 transactions and the March 13 award under the company's director compensation policy. The filing also clarifies Denner's indirect position through Sarissa Capital Management LP and related funds.

Investors and market participants reviewing insider activity, company results, analyst updates, and credit-agreement status will find the filings and disclosures relevant to assessing near-term market behavior for IRWD shares. The company continues to provide guidance for 2026 while publicly confirming compliance with its credit agreement's liquidity terms.

Risks

  • Near-term share-price volatility - the stock fell nearly 12% over the prior week, indicating market sensitivity that could affect investor returns in the healthcare and broader equities markets.
  • Earnings and revenue shortfalls - Q4 2025 results missed forecasts for EPS and revenue, introducing uncertainty for pharmaceutical revenue and cash-flow projections.
  • Insider selling at scale - the director's $20.5 million sale could be perceived by some market participants as a negative signal, potentially influencing sentiment in the biotech and healthcare sectors.

More from Insider Trading

Guidewire CEO Executes $192,000 Stock Sale as Shares Trade Below Recent Highs Mar 17, 2026 SLR Investment Director Adds Nearly Half-Million in Stock as Dividend Yield Stays Elevated Mar 17, 2026 Coliseum Capital Adds $3.07M to Sonos Stake Through March Purchases Mar 17, 2026 Reddit Director Increases Stake With $1.38 Million Purchase Mar 17, 2026 MP Materials General Counsel Sells $834,979 in Stock as Company Posts Mixed Q4 Results Mar 17, 2026